



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

22 January 2024
EMA/INS/GMP/30230/2024
European Medicines Agency

Highlights from the 12th meeting of the Nitrosamine Implementation Oversight Group (NIOG)

- NIOG took note of the procedural, safety, and quality developments reflected in Q&A revision 20, concerning the call for review, the enhanced Ames test acceptability and reporting requirements for non-mutagenic nitrosamine impurities. NIOG was also informed on policy updates that will be implemented in the network starting in 2024 concerning the process-flow for Acceptable Intake limit establishment.
- NIOG discussed the applicability of the Less than lifetime (LTL) approach for authorised products and taking note of ongoing MAAs.
- The points raised by industry concerning the implementation of Carcinogenic Potency Categorization Approach (CPCA) and enhanced Ames test (EAT) approaches were also discussed in advance of the 6th NIOG-IP meeting.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union

